2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of …
SR Das, BM Everett, KK Birtcher, JM Brown… - Journal of the American …, 2020 - jacc.org
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk
Reduction in Patients With Type 2 Diabetes: A Report of the American College of …
Reduction in Patients With Type 2 Diabetes: A Report of the American College of …
Association of glycemic indices (hyperglycemia, glucose variability, and hypoglycemia) with oxidative stress and diabetic complications
E Papachristoforou, V Lambadiari… - Journal of diabetes …, 2020 - Wiley Online Library
Oxidative stress (OS) is defined as a disturbance in the prooxidant‐antioxidant balance of
the cell, in favor of the former, which results in the antioxidant capacity of the cell to be …
the cell, in favor of the former, which results in the antioxidant capacity of the cell to be …
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
JR Ussher, DJ Drucker - Nature Reviews Cardiology, 2023 - nature.com
Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary …
Health professionals are encouraged to take the ESC Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …
exercising their clinical judgment, as well as in the determination and the implementation of …
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes …
AJ Garber, Y Handelsman, G Grunberger, D Einhorn… - Endocrine Practice, 2020 - Elsevier
ABSTRACT Abbreviations: A1C= hemoglobin A1C; AACE= American Association of Clinical
Endocrinologists; ABCD= adiposity-based chronic disease; ACCORD= Action to Control …
Endocrinologists; ABCD= adiposity-based chronic disease; ACCORD= Action to Control …
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular …
Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their
structure and duration of action and have been studied in trials of varying sizes and with …
structure and duration of action and have been studied in trials of varying sizes and with …
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
HC Gerstein, HM Colhoun, GR Dagenais, R Diaz… - The Lancet, 2019 - thelancet.com
Background Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce
cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high …
cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high …
Therapeutic pipeline in nonalcoholic steatohepatitis
R Vuppalanchi, M Noureddin, N Alkhouri… - Nature Reviews …, 2021 - nature.com
Our understanding of nonalcoholic fatty liver disease pathophysiology continues to advance
rapidly. Accordingly, the field has moved from describing the clinical phenotype through the …
rapidly. Accordingly, the field has moved from describing the clinical phenotype through the …
[HTML][HTML] GLP-1 physiology informs the pharmacotherapy of obesity
DJ Drucker - Molecular metabolism, 2022 - Elsevier
Background Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …
GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes
Patients with type 2 diabetes are at high risk for development of cardiovascular disease,
including myocardial infarction, stroke, heart failure, and cardiovascular death. Multiple large …
including myocardial infarction, stroke, heart failure, and cardiovascular death. Multiple large …